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Abstract
Background: Uveal melanoma (UM) is the most common primary intraocular malignant tumor in
adults, and nearly 40% of UM will develop metastasis that will ultimately lead to death. The Epithelial
Cell Adhesion Molecule (EpCAM) is a type I transmembrane glycoprotein expressed by carcinomas
of head and neck, ovary, colon, breast, kidney and lung. Recently, antibodies against EpCAM such
as Edrecolomab and Catumaxomab were developed, and clinical trials with these antibodies have
been used in several types of neoplasia. We studied the expression of EpCAM in UM.
Methods: 25 enucleated formalin-fixed, paraffin-embedded UM specimens were immunostained
for EpCAM. Histopathological analysis of the specimens with regards to prognostic factors such as
cell type, largest (linear) tumor dimension, number of mitotic figures, scleral invasion and tumor
infiltrating lymphocytes were done.
Results: None of them was positive for this EpCAM.
Conclusion:  In our report, UM did not express EpCAM. Therefore, it is not a helpful
immunohistochemical marker to predict the behavior of UM. Further studies are needed to verify
if EpCAM could also be related with prognosis and treatment of UM.
Background
Uveal melanoma (UM) is the most common primary
intraocular malignant tumor in adults and encompass
nearly 85% of all ocular melanoma[1]. The worldwide
incidence of UM is 5.3 to 10.9 cases per million popula-
tion comprising about 4,25% of all melanomas[1]. Even
with the progress of diagnosis and treatment methods, in
the last 25 years the UM mortality is almost unaltered[1].
Nearly 40% of UM will develop metastasis that will ulti-
mately lead to death; therefore, a better understanding of
the cellular and molecular mechanisms of UM is essential
in order to develop novel and specific drugs to prevent or
treat UM metastasis. It has been postulated that the high
malignancy of cutaneous[2] and uveal melanomas[3]
could be connected with an increased cytokeratin expres-
sion, an epithelial cell marker.
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Novel drugs that target cell surface antigens, signalling
pathways, or critical effector molecules are in evidence in
cancer research. We previously demonstrated that the
majority of UM are positive for C-kit, a tyrosine kinase
receptor, and UM cells impressively decreased the prolif-
eration and invasion rates when exposed to imatinib
mesylate, the C-kit inhibitor[4].
The Epithelial Cell Adhesion Molecule (EpCAM) discov-
ered in the early 1980's is a type I transmembrane glyco-
protein encoded by the ga733-2 gene on chromosome 4
(locus 4q). It is detected at the basolateral membrane of
the majority of epithelial tissue such as simple, pseudoes-
tratified and transitional epithelium. However, in mature
squamous stratified epithelium and in hepatocytes,
EpCAM is negative [5-10]. Prior studies reported that
EpCAM express in a variety of epithelial neoplasias, like
carcinomas of head and neck, ovary, colon, breast, kidney
and lung[5,9,11]. EpCAM immunoreactivity was also
found in squamous pre-malignant lesions[5].
Recently, antibodies against EpCAM such as Edrecolomab
and Catumaxomab were developed. Clinical trials with
these antibodies has been used in patients with Colon,
Breast, Head and Neck, Ovary and Gastrointestinal carci-
nomas [11-15].
Until now, immunoreactivity against Ep-CAM has not
been previously described in UM. The aim of this research
is to study the expression of EpCAM in UM.
Materials and methods
UM specimens obtained by enucleation between 1980
and 2004 were collected from the archives of the Henry C.
Witelson Ocular Pathology Laboratory and Registry,
McGill University, Montreal, Canada. Each specimen was
formalin-fixed, paraffin-embedded and contained suffi-
cient material for H&E and immunohistochemistry.
Tumors presenting extensive necrosis that precluded an
appropriate evaluation of histopathological features were
excluded.
Histopathological analysis of the specimens with regards
to prognostic factors such as cell type (modified Cal-
lender's classification) largest (linear) tumor dimension
(LTD), number of mitotic figures in 40 high power fields
(HPF) (400×), scleral invasion and tumor infiltrating lym-
phocytes (TIL) in 20 HPF were done. For the purpose of
statistical analysis, tumors where classified as having a low
mitotic rate (0–1 mitotic figures in 40 HPF) or a high
mitotic rate (2 or more mitotic figures in 40 HPF). These
parameters have been previously used in past studies. The
presence of TIL was classified as low (< 200 lymphocytes
in 20 HPF) or high (> 200 lymphocytes in 20 HPF)
according to a previous publication.
Immunohistochemistry was performed using the mono-
clonal anti-EpCAM antibody VU-1D9 (ab11293 – abcam,
Cambridge, MA, USA). The antibody was applied at a
dilution of 1:70 for 18 h at 4°C, after 15 minutes in 10
nmol/l citrate buffer (pH 6.0) for antigen retrieval. Endog-
enous peroxidase was blocked using 0.3% hydrogen per-
oxidase diluted in methanol for 10 minutes. A standard
avidin-biotin complex (ABC) technique using 3 amino-9
ethyl-carbazole was used for visualization. A case of colon
adenocarcinoma was used as a positive control. Negative
control sections were incubated with normal rabbit serum
instead of the primary antibody.
After tissue processing, all cells that displayed distinct
immunoreactivity were considered positive, regardless of
intensity. Negative expression was determined by absence
of the immunostain.
Statistical analysis was performed using a computer soft-
ware (Statistical Package for the Social Sciences" version
11.5 (SSPS Inc., Chicago, IL, USA)). The categorical varia-
bles such as cell type (spindle or epithelioid), scleral inva-
sion, mitosis (0–1 or ≥2 in 40 HPF) and TIL (0–200 or >
200 in 20 HPF) were analyzed. The chi-square test was
used to assess statistical significance and a p value of less
than 0.05 was considered significant.
Results
The results are displayed in table 1.
Twenty-nine cases of UM were retrieved, and four cases
were excluded due to extensive tumor necrosis. The 25
UM specimens studied presented the following cell types:
18 mixed, 5 epithelioid and 2 spindle. Scleral invasion
was observed in 8% of the studied cases (n = 2). The
tumor infiltrating lymphocyte index was low in 76% of
the cases (n = 19) and high in 24% of the remaining cases
(n = 6). Approximately 56% of cases presented 2 or more
mitotic figures in 40 HPF (n = 14) and the remaining had
1 or less (n = 11). The mean average of the LTD was 9,9
mm.
All the 25 specimens demonstrated negative staining to
EpCAM. There was no expression of this protein in any
part of the enucleated specimens (figure 1).
Discussion
EpCAM was described under several names originated
from the respective monoclonal antibodies (KSA, ga733-
2, 17-1a antigen, mh99, aua 1, moc31) [5-8]. It mediates
Ca2+ independent homotypic cell-cell adhesions and was
correlated with the preservation of cellular adhesion [5-
10]. Previous studies demonstrated that the overexpres-
sion of EpCAM had a negative efect on E-cadherin medi-
ated cell-cell adhesion and upregulated the proto-Cancer Cell International 2006, 6:26 http://www.cancerci.com/content/6/1/26
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oncogene c-myc and cyclin A/E[16]. Based on these previ-
ous observations, EpCAM might be related with dedifer-
entiation, proliferation and tumoral invasion[5,16].
EpCAM is expressed in several types of epithelial
tumors[5,17]. EpCAM overexpression is correlated with
poor disease free suvival in breast cancer[18], and loss of
EpCAM expression in gastric adenocarcinoma has been
reported to be associated with poor TNM staging progno-
sis[10], although inconsistent[19]. It is also detected
weakly and occasionally in types of cancer other than car-
cinoma as fibrosarcoma, angiosarcoma, amd estesioneu-
roblastoma[17].
Some cases of cutaneous melanoma stains for epithelial
markers[20], and most of them are metastatic lesions[21],
meaning, more aggressive tumors. Also, UM cases that
express cytokeratin proteins, a phenomenon that have
been called interconverted phenotype, are correlated with
poor prognosis[3]. In such cases, EpCAM, as an epithelial
antigen, could be expected to be positive. Further studies
of EpCAM with known cytokeratin positive UM tumors
could confirm if there is any relationship between EpCAM
and UM.
The reason of testing EpCAM in UM is the anti-EpCAM
drugs avaiable to treat some malignant tumors. Edrecolo-
mab is a monoclonal Anti-EpCAM antibody (Co17-1A
antigen). In studies using Edrecolomab as adjuvant ther-
apy, there was elimination of bone marrow micrometas-
tases from Breast cancer[13]. Also, Edrecolomab has been
tested in patients with colon cancer stages II and III, but
without improvement in overall or disease-free survival,
even when added with fluorouracil and folinic
acid[14,22].
Catumaxomab is a bispecific trifunctional antibody
(trAb) (anti-EpCAM × anti-CD3) and belongs to a new
class of intact antibodies. The two binding sites of this
antibody are against EpCAM positive tumor cells and T
cells (CD3+). At the same time, this is mediated by the Fc-
region, which binds to Fc3 – receptors I and III on acces-
sory cells (macrophages, natural killer cells, dendritic
cells). This results in higher tumor killing than the mono-
clonal antibodies mentioned[11,12,15,23]. Recently,
there are promising results with Catumaxomab in treat-
ment of malignant ascites associated with Ovarian cancer,
Non-small cell Lung Cancer and Peritoneal Carcinomato-
sis due to Gastrointestinal Cancer[12,15,23].
Table 1: The histopathological features of the UM cases.
Case Cell type Scleral Invasion TIL Mitosis LTD (mm) EpCAM
1MNLH 1 3 N e g
2 M N L L 7 Neg
3MNLH 1 2 N e g
4 M N L H 9 Neg
5EYH H 1 8 N e g
6 M N L L 5 Neg
7 M N L L 8 Neg
8 M N L H 8 Neg
9 M N L L 5 Neg
10 E N H H 14 Neg
11 M N L L 7 Neg
12 M N L L 9 Neg
13 M N L L 9 Neg
14 S N L L 4 Neg
15 M N H H 12 Neg
16 M N L H 13 Neg
17 M N L H 11 Neg
18 E Y H H 16 Neg
19 M N L L 7 Neg
20 M N L H 11 Neg
21 E N H H 13 Neg
22 M N L L 6 Neg
23 S N L L 4 Neg
24 E N H H 14 Neg
25 M N L H 12 Neg
TIL: tumor infiltrating lymphocytes; LTD: largest tumor dimension; M: mixed cell type; E: epithelioid cell tupe; S: spindle cell type; N: no; Y: yes; H: 
high; L: low; Neg: negative expression.Cancer Cell International 2006, 6:26 http://www.cancerci.com/content/6/1/26
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We made an effort to detect EpCAM expression in 25
selected cases of uveal melanoma; however, none of them
were positive, even in the UM epithelioid cell type.
Conclusion
EpCAM is overexpressed in a variety of epithelial neopla-
sias. The development of adjuvant therapy targeted
against EpCAM, in the future, may help increase patient
survival in this set of patients. In our report, UM did not
express EpCAM. Therefore, it is not a helpful immunohis-
tochemical marker to predict the behavior of UM. Further
studies are needed to verify if EpCAM could also be
related with prognosis and treatment of UM.
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